

# EVALUATION OF THE USE OF USTEKINUMAB IN THE CLINICAL PRACTICE AND ITS ECONOMIC IMPACT

Colón López de Dicastillo A; Gómez Gómez D, Illaro Uranga, A;  
Mayorga Pérez, J; Valero Domínguez M.

Pharmacy Department. Marqués de Valdecilla University Hospital.

## INTRODUCTION

- **Ustekinumab**, whose commercialization lead to a significant reduction in the number of administered doses (1-2 injections every 12 weeks according to the weight), represents an **alternative therapy in** the treatment of severe **psoriasis**.
- It has been observed that **Ustekinumab posology is modified** depending on the patient's response in the daily clinical practice.

## OBJECTIVE


To **evaluate** and to **calculate** the **economic impact** of the use of Ustekinumab in a tertiary care hospital during the daily clinical practice.

## METHODS


- Observational retrospective study of patients treated at least, during **28 weeks** with Ustekinumab between January/2009 and January/2013.
- Data collected:
  - patient's weight, posology, and duration of treatment
  - real and theoretical costs per patient/year in relation to the patient's weight.
- Ustekinumab 45 mg syringe  $\longleftrightarrow$  **3.174,3 € (official data)**

## RESULTS


### PATIENTS PER WEIGHT



### AVERAGE COST PER PATIENT/YEAR



### AVERAGE COST PER PATIENT/YEAR PER WEIGHT



**>100 Kg** They received a 73,2% of all recommended doses, because of the reduction of Ustekinumab doses from 90 to 45 mg and to the shortening of the dosage interval. This means a cost-saving of 26,7% (7900,3 €).

**<100 Kg** They received 102% of all the recommended doses due to some reductions in dosage interval.

## CONCLUSION

During this analyzed period of time, the pharmaceutical expense in Ustekinumab has been **lower than expected**, principally, because modifications of posology in the >100 kg patients. Nevertheless, it is necessary to evaluate if all the changes introduced in these patient's posology have a clinical impact in the efficacy of the treatment of their psoriasis.